|Allergy Therapeutics PLC (LON:AGY) Rating
The financial company have set price target of GBX 53.00 on Allergy Therapeutics PLC (LON:AGY) shares. This is 130.43% from the last stock close. In a note made public on Wednesday, 2 November, Panmure Gordon maintained their Buy rating on shares of AGY.
Allergy Therapeutics plc (LON:AGY) Ratings Coverage
Out of 3 analysts covering Allergy Therapeutics PLC (LON:AGY), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. GBX 79 is the highest target while GBX 37 is the lowest. The GBX 54 average target is 130.38% above today’s (GBX 23.44) stock price. Allergy Therapeutics PLC has been the topic of 26 analyst reports since July 23, 2015 according to StockzIntelligence Inc. Panmure Gordon maintained the stock with “Buy” rating in Friday, June 10 report. On Monday, September 26 the stock rating was maintained by Numis Securities with “Buy”. Panmure Gordon maintained the stock with “Buy” rating in Monday, September 21 report. The rating was maintained by Panmure Gordon on Wednesday, November 2 with “Buy”. The stock of Allergy Therapeutics plc (LON:AGY) has “Buy” rating given on Monday, October 10 by Panmure Gordon. Panmure Gordon maintained Allergy Therapeutics plc (LON:AGY) rating on Wednesday, January 13. Panmure Gordon has “Buy” rating and GBX 51 price target. The firm has “Buy” rating given on Monday, December 7 by Panmure Gordon. Panmure Gordon maintained it with “Buy” rating and GBX 47 target price in Thursday, July 23 report. The rating was maintained by Panmure Gordon on Monday, August 10 with “Buy”. The rating was maintained by Panmure Gordon on Tuesday, September 1 with “Buy”.|
|Trading update last year was on 17th of November|
2 November 2016
Allergy Therapeutics plc
("Allergy Therapeutics" or the "Company")
European Patent Office grants new and expanded patent underpinning Allergy Therapeutics' core Microcrystalline Tyrosine technology
Patent already granted in the United Kingdom and New Zealand
Allergy Therapeutics (AIM:AGY), the fully integrated pharmaceutical company specialising in allergy vaccines, today announces that the European Patent Office has granted a broad technology patent relating to the Company's unique Microcrystalline Tyrosine (MCT) depot adjuvant manufacturing process. This patent covers the novel manufacture and physiochemical characteristics of MCT in combination with one or more antigens, further strengthening the Company's core intellectual property.
The granting of this patent further strengthens Bencard Adjuvant Systems, the wholly-owned division of Allergy Therapeutics which specialises in developing and optimising aluminium-free adjuvants for infectious diseases. Recent data generated have shown how MCT has a synergistic effect when coupled with another adjuvant from BAS's portfolio, Virus Like Particles (VLP), to create the adjuvant system AdSys-VcT. As recently announced, this adjuvant system demonstrated protective efficacy in a malaria model in a study performed in collaboration with the University of Oxford, UK.
Manuel Llobet, Chief Executive Officer of Allergy Therapeutics, commented: "We are pleased to expand this key patent and are excited by the potential for MCT as a core technology within our adjuvant portfolio to create novel and efficacious vaccines, both in allergies and also in infectious disease areas such as malaria and influenza. This further underpins the future pipeline for products, and the long term success of Allergy Therapeutics to continue innovating and producing novel medicines."|
|Heading back in to top-up territory|
|I don't know about The Duke of York, to-day is more of a Humpty Dumpty day!
|Well sticking with the Duke of York analogy, we walked only part the way up the hill only to be walked back down again!|
|They have said they will meet with FDA in 2016 so I guess it depends if they RNS the outcome. As for the SP, who knows but it's fun to speculate! I think there's a bit more of a leg up to come this week then we'll stay close to 30.|
I personally would be surprised if there was any news in relation to the USA until early in 2017 and possibly with the interims. I expect that trials are now anticipated in 2018 but I could of course be well off the mark.
Apart from that I expect to see it around this price at the close tomorrow. Still a lot of re-assuring to do here. There is of course an increasing amount of potential news sources.
|Well I was hoping we may have seen a 5-6p leap today taking us to 30p but 3p is fine, especially if we get similar tomorrow! Higher volume than usual today. Hopefully we will soon get some news of their discussions with FDA regarding the repeat dose-ranging finding study protocol which should help cement the new timelines for the US opportunity.|
|We look a little like The Grand Old Duke of York to-day!
|The word is on the street
|Eventful week! Lots of things lining up to keep the share price momentum moving north. 30p could be on the cards next week....would be exciting if it hit 30 on Monday now we are out of overhang territory.|
In a week when the FTSE 100 finally made an all-time high there were surprisingly few big winners among either the large or mid-caps. A three-day losing streak for the blue-chip index clearly took some froth out of the market, which is why we cast our net a bit wider in search of our Share of the week.
In fact, we headed all the way to AIM where an old favourite was causing a stir.
We last covered Allergy Therapeutics (AGY) in September following full-year results. Revenue had risen fast, but heavy R&D spend meant big full-year losses and a possible delay to profitability.
However, one analyst reckoned an enterprise value (EV)/sales ratio of just 1.6 times made the shares "very cheap", with peers trading on a ratio of three times. It's why Paul Cuddon at Numis slapped a 37p price target on the shares.
That article - Allergy Therapeutics tipped to bounce back - was nearly three weeks ago, and things have really taken off since.
In the days following our write-up, directors opened their wallets, snapping up 280,000 Allergy shares at 17.75-19.25p. Chief executive Manuel Llobet kicked things off, buying 100,000 at 18p. Finance director Nicolas Wykeman picked up 150,000 at 17.75p, before chairman Peter Jensen bagged 30,000 at 19.25p.
This Friday, the share price peaked at 25p, up 45% since the results. It's also a five-month high, and just a penny from the 50% Fibonacci retracement of the decline from the October 2015 best at 35p.
Clearly, the market also liked news Monday that Allergy would present data at the World Vaccine Congress, demonstrating how its adjuvants can make "significant improvements" in the effectiveness of malaria vaccines.
Data also implies "highly significant" potential for this novel adjuvant system in infectious disease applications using Allergy's Bencard Adjuvant Systems (BAS) technology, we're told.
Panmure Gordon has been a fan for ages, and remains a buyer, believing Allergy could be worth 53p a share in time. The broker's sum-of-the-parts valuation is based on enterprise value/sales analysis of specialty pharma and allergy peers for calendar year 2017, estimated balance sheet cash and net present value of its Pollinex Quattro hay fever treatment.|
|Monday is likely to be very interesting as AGY has been tipped as THE SHARE OF THE WEEK in Interactive Investor (iii) and that benchmark of 37p price from Paul Cuddon is again mentioned.
There has been very solid progress here and the recent good news has not really shown in the share price due to a large overhang from a sell order placed by an insti following the recent setback on the USA trials.
That overhang has now cleared by the look of to-days movement. I thought it strange the mm's upping the bid price so late in the day and thought to myself that they are keen for this stock. Now I know why!
Good to see AGY be recognised at last. We are still very much at the start of the journey.
|BENCARD....Very impressive! impo
Well absolutely yes, but better than that it suggests that their Adjuvant might have even wider applicability beyond these areas. Think of the potential implications....
Hypothetically, if Allergy's adjuvant can make other vaccines more effective then that can be patented as a new patent and will extend the life of a Pharma Co's existing product. The value proposition will be pretty evident to the vaccine owner that would, I suggest, have to fund the improved formula through the approval process. Allergy would only need to license their adjuvant to the Pharma for its specific use.
|Currently travelling in the USA so only just seen yesterday's news. Its a bit left field but it just shows how much they can leverage the technology they have and also that management appear to be well placed when it comes to partnering with those best placed to benefit from the application of their novel adjuvant systems. When you think that AGY could soon be major players in malaria, peanut allergy and grass allergy, the potential for revenue growth is fairly huge.|
|It appears as if we have been taken off the naughty boy step!
|I was at the Proactive meeting too jimmyloser and the Shares Magazine presentation the week before
Both slides sets are now available and the video from the shares Mag presentation (see links below)
I bought a few on the strength of the Shares Mag presentation and the recent director share buying.
Regarding the announcement today, as you say, it was a bit left field as malaria was not even mentioned at either of the two recent presentations|
|This mornings RNS came from 'left of field' for me but is really interesting to see the width of AGY.
Allergy Therapeutics presents enhanced efficacy data in a malaria vaccine model with its novel adjuvant system. Data to be presented today at the World Vaccine Congress demonstrates "significant improvements" in effective infectious disease applications using Bencard Adjuvant Systems technology.
|I attended the Proactive forum last evening and enjoyed a very positive message and presentation from the CEO.
I came away with a feeling that positive opportunities are all around us and are being managed in a sensible way.
It appears that the company were really puzzled by the failure of the USA trials.
The large overhang has been cleared it is believed. Will we see a holdings notice?
All seems to be good for the medium/longer term shareholder.
Anyone over the age of 95 may wish to consider carefully this opportunity.
|HARDMAN & CO UPDATE